ThermoGenesis (THMO) 10-Q 13 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 09, 2019
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	0000811212
Trading Symbol	kool
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		2,416,337
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,424,000	$ 2,400,000
Accounts receivable, net of allowance for doubtful accounts of $398,000 ($419,000 at December 31, 2018)	3,091,000	1,509,000
Inventories, net of reserves of $384,000 ($258,000 at December 31, 2018)	3,951,000	4,493,000
Prepaid expenses and other current assets	389,000	224,000
Total current assets	9,855,000	8,626,000
Restricted cash	1,000,000	1,000,000
Equipment and leasehold improvements, net	2,398,000	2,562,000
Right-of-use operating lease assets, net	915,000
Goodwill	781,000	781,000
Intangible assets, net	1,531,000	1,591,000
Other assets	52,000	51,000
Total assets	16,532,000	14,611,000
Current liabilities:
Accounts payable	3,198,000	2,423,000
Accrued payroll and related expenses	485,000	703,000
Deferred revenue	577,000	485,000
Interest payable – related party	926,000	1,513,000
Other current liabilities	1,295,000	1,241,000
Total current liabilities	6,481,000	6,365,000
Convertible promissory note – related party, less debt discount of $6,367,000 ($6,026,000 at December 31, 2018)	2,346,000	1,174,000
Convertible promissory note, less debt discount of $743,000 ($0 at December 31, 2018)	57,000
Derivative obligations	1,000	1,000
Long term operating lease obligations	825,000
Other non-current liabilities	322,000	340,000
Total liabilities	10,032,000	7,880,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 2,368,337 issued and outstanding (2,168,337 at December 31, 2018)	2,000	2,000
Paid in capital in excess of par	236,343,000	235,888,000
Accumulated deficit	(230,603,000)	(227,435,000)
Accumulated other comprehensive loss	(20,000)	(13,000)
Total Cesca Therapeutics Inc. stockholders’ equity	5,722,000	8,442,000
Noncontrolling interests	778,000	(1,711,000)
Total equity	6,500,000	6,731,000
Total liabilities and stockholders’ equity	$ 16,532,000	$ 14,611,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 398,000	$ 419,000
Inventories, reserves	384,000	258,000
Debt discount	$ 743,000	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	2,368,337	2,168,337
Common stock, shares outstanding (in shares)	2,368,337	2,168,337
Convertible Promissory Note [Member]
Debt discount	$ 6,367,000	$ 6,026,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net revenues	$ 4,305,000	$ 2,004,000	$ 7,268,000	$ 3,871,000
Cost of revenues	2,354,000	1,641,000	4,057,000	3,156,000
Gross profit	1,951,000	363,000	3,211,000	715,000
Expenses:
Sales and marketing	384,000	359,000	725,000	685,000
Research and development	611,000	908,000	1,175,000	1,949,000
General and administrative	1,218,000	2,399,000	2,478,000	4,641,000
Impairment Charges		27,202,000		27,202,000
Total operating expenses	2,213,000	30,868,000	4,378,000	34,477,000
Loss from operations	(262,000)	(30,505,000)	(1,167,000)	(33,762,000)
Fair value change of derivative instruments	0	308,000	0	567,000
Interest expense	(1,211,000)	(733,000)	(2,343,000)	(1,093,000)
Other expenses	(2,000)	(32,000)	(11,000)	(44,000)
Total other expense	(1,213,000)	(457,000)	(2,354,000)	(570,000)
Loss before benefit for income taxes	(1,475,000)	(30,962,000)	(3,521,000)	(34,332,000)
Benefit for income taxes		3,451,000		3,451,000
Net loss	(1,475,000)	(27,511,000)	(3,521,000)	(30,881,000)
Loss attributable to noncontrolling interests	(178,000)	(503,000)	(354,000)	(913,000)
Net loss attributable to common stockholders	(1,297,000)	(27,008,000)	(3,167,000)	(29,968,000)
Net loss	(1,475,000)	(27,511,000)	(3,521,000)	(30,881,000)
Other comprehensive loss:
Foreign currency translation adjustments	(3,000)	21,000	(8,000)	28,000
Comprehensive loss	(1,478,000)	(27,490,000)	(3,529,000)	(30,853,000)
Comprehensive loss attributable to noncontrolling interests	(178,000)	(503,000)	(354,000)	(913,000)
Comprehensive loss attributable to common stockholders	$ (1,300,000)	$ (26,987,000)	$ (3,175,000)	$ (29,940,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.47)	$ (17.49)	$ (1.21)	$ (22.73)
Weighted average common shares outstanding – basic and diluted (in shares)	2,784,776	1,544,412	2,623,989	1,318,438

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017	1,090,664
Balance at Dec. 31, 2017	$ 1,000	$ 221,381,000	$ (187,640,000)	$ (43,000)	$ (487,000)	$ 33,212,000
Stock-based compensation expense		137,000				137,000
Foreign currency translation				7,000		7,000
Net loss			(2,960,000)		(410,000)	(3,370,000)
Issuance of pre-funded warrants in financing, net of offering costs		1,213,000				1,213,000
Issuance of common stock and pre-funded warrants, net of offering costs (in shares)	60,967
Cumulative-effect adjustment from adoption of ASC 606 | Accounting Standards Update 2014-09 [Member]			(79,000)			(79,000)
Balance (in shares) at Mar. 31, 2018	1,151,631
Balance at Mar. 31, 2018	$ 1,000	222,731,000	(190,679,000)	(36,000)	(897,000)	31,120,000
Balance (in shares) at Dec. 31, 2017	1,090,664
Balance at Dec. 31, 2017	$ 1,000	221,381,000	(187,640,000)	(43,000)	(487,000)	33,212,000
Foreign currency translation						28,000
Balance (in shares) at Jun. 30, 2018	2,068,337
Balance at Jun. 30, 2018	$ 2,000	227,712,000	(217,687,000)	(15,000)	(1,400,000)	8,612,000
Balance (in shares) at Mar. 31, 2018	1,151,631
Balance at Mar. 31, 2018	$ 1,000	222,731,000	(190,679,000)	(36,000)	(897,000)	31,120,000
Stock-based compensation expense		163,000				163,000
Exercise of pre-funded warrants (in shares)	269,167
Exercise of pre-funded warrants		27,000				27,000
Foreign currency translation				21,000		21,000
Net loss			(27,008,000)		(503,000)	(27,511,000)
Issuance of pre-funded warrants in financing, net of offering costs	$ 1,000	4,791,000				4,792,000
Issuance of common stock and pre-funded warrants, net of offering costs (in shares)	647,497
Stock-based compensation expense (in shares)	42
Balance (in shares) at Jun. 30, 2018	2,068,337
Balance at Jun. 30, 2018	$ 2,000	227,712,000	(217,687,000)	(15,000)	(1,400,000)	8,612,000
Balance (in shares) at Dec. 31, 2018	2,168,337
Balance at Dec. 31, 2018	$ 2,000	235,888,000	(227,435,000)	(13,000)	(1,711,000)	6,731,000
Stock-based compensation expense		81,000				81,000
Exercise of pre-funded warrants (in shares)	50,000
Exercise of pre-funded warrants		5,000				5,000
Discount due to beneficial conversion features		1,513,000				1,513,000
Reorganization of subsidiary and related change in non-controlling interest		(2,843,000)			2,843,000
Foreign currency translation				(4,000)		(4,000)
Net loss			(1,871,000)		(176,000)	(2,047,000)
Balance (in shares) at Mar. 31, 2019	2,218,337
Balance at Mar. 31, 2019	$ 2,000	234,644,000	(229,306,000)	(17,000)	956,000	6,279,000
Balance (in shares) at Dec. 31, 2018	2,168,337
Balance at Dec. 31, 2018	$ 2,000	235,888,000	(227,435,000)	(13,000)	(1,711,000)	6,731,000
Foreign currency translation						(8,000)
Balance (in shares) at Jun. 30, 2019	2,368,337
Balance at Jun. 30, 2019	$ 2,000	236,343,000	(230,603,000)	(20,000)	778,000	6,500,000
Balance (in shares) at Mar. 31, 2019	2,218,337
Balance at Mar. 31, 2019	$ 2,000	234,644,000	(229,306,000)	(17,000)	956,000	6,279,000
Stock-based compensation expense		125,000				125,000
Exercise of pre-funded warrants (in shares)	150,000
Exercise of pre-funded warrants		18,000				18,000
Discount due to beneficial conversion features		800,000				800,000
Reorganization of subsidiary and related change in non-controlling interest					2,843,000
Foreign currency translation				(3,000)		(3,000)
Net loss			(1,297,000)		(178,000)	(1,475,000)
Issuance of pre-funded warrants in financing, net of offering costs		756,000				756,000
Balance (in shares) at Jun. 30, 2019	2,368,337
Balance at Jun. 30, 2019	$ 2,000	$ 236,343,000	$ (230,603,000)	$ (20,000)	$ 778,000	$ 6,500,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (3,521,000)	$ (30,881,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	402,000	333,000
Stock based compensation expense	206,000	300,000
Amortization of debt discount	1,229,000	350,000
(Recovery of) reserve for excess and slow-moving inventories	125,000	(252,000)
Change in fair value of derivative obligation	0	(567,000)
Deferred income tax benefit		(3,451,000)
Loss on disposal of equipment	6,000	420,000
Impairment of intangible asset		27,202,000
Net change in operating assets and liabilities:
Accounts receivable	(1,582,000)	869,000
Inventories	449,000	(358,000)
Prepaid expenses and other assets	(165,000)	257,000
Accounts payable	749,000	(242,000)
Related party payable		(606,000)
Accrued payroll and related expenses	(217,000)	50,000
Deferred revenue	92,000	254,000
Other current liabilities	(623,000)	217,000
Other noncurrent liabilities	(61,000)	3,000
Net cash used in operating activities	(2,911,000)	(6,102,000)
Cash flows from investing activities:
Capital expenditures	(142,000)	(850,000)
Net cash used in investing activities	(142,000)	(850,000)
Cash flows from financing activities:
Payments on financing lease obligations	(15,000)	(19,000)
Proceeds from long-term debt	800,000	500,000
Proceeds from related party line of credit	1,513,000
Proceeds from exercise of pre-funded warrants	23,000
Proceeds from issuance of common stock and prefunded warrants, net	756,000	6,032,000
Net cash provided by financing activities	3,077,000	6,513,000
Effects of foreign currency rate changes on cash and cash equivalents		(3,000)
Net increase (decrease) in cash, cash equivalents and restricted cash	24,000	(442,000)
Cash, cash equivalents and restricted cash at beginning of period	3,400,000	3,513,000
Cash, cash equivalents and restricted cash at end of period	3,424,000	3,071,000
Supplemental disclosures of cash flow information:
Cash paid for interest	1,668,000	657,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt	2,313,000
Right-to-use asset acquired under operating lease	966,000
Transfer of equipment to inventories	33,000	172,000
Transfer of inventories to equipment		$ 420,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company”), a Delaware corporation, develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company was founded in 1986 ® ® ® On January 1, 2019, July 2017 20% 20% 80% 100% The Company reacquired the non-controlling interest shares in ThermoGenesis with a deficit of $1,711,000 20% $1,100,000. $2,843,000 Cesca is an affiliate of the Boyalife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not May 30, 2019, May 30, 2019. All historical share amounts disclosed herein have been retroactively recast to reflect the reverse split and subsequent share exchange. No Liquidity and Going Concern The Company has a Revolving Credit Agreement (Credit Agreement) with Boyalife Asset Holding II, Inc. (Refer to Note 3 June 30, 2019, $8,713,000 $10,000,000 may may no On April 18, 2019, “April 444,445 $1.70 $756,000. April April 26, 2019 Each pre-funded warrant is immediately exercisable for one $0.10 not 4.99% 9.99%, may not 61st may not 9.99%. Subject to certain exceptions, in the event the Company sells or issues any shares of common stock or common stock equivalents at a lower price during the period beginning on the closing date of the April three sixty-five 365 At June 30, 2019, $2,424,000 $3,374,000. June 30, 2019 $230,603,000. one The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The condensed consolidated financial statements include the accounts of Cesca and its wholly-owned subsidiaries, ThermoGenesis and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis’ majority-owned subsidiary, CARTXpress. All significant intercompany accounts and transactions have been eliminated upon consolidation. Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. three six June 30, 2019 not may December 31, 2019. 10 December 31, 2018.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Recently Adopted Accounting Standards In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 January 1, 2019. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000. Revenue Recognition Revenue is recognized based on the five 606: The following tables summarize the revenues of the Company’s reportable segments: Three Months Ended June 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 3,028,000 $ 54,000 $ 3,082,000 BioArchive 433,000 351,000 784,000 CAR-TXpress 182,000 -- 182,000 Manual Disposables 205,000 -- 205,000 Other -- -- $ 8,000 8,000 Total Device Segment 3,848,000 405,000 8,000 4,261,000 Clinical Development Segment: Disposables 37,000 -- -- 37,000 Other -- 7,000 -- 7,000 Total Clinical Development 37,000 7,000 -- 44,000 Total $ 3,885,000 $ 412,000 $ 8,000 $ 4,305,000 Six Months Ended June 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,295,000 $ 109,000 $ 4,404,000 BioArchive 1,031,000 766,000 1,797,000 Manual Disposables 499,000 -- 499,000 CAR-TXpress 490,000 -- 490,000 Other -- -- $ 22,000 22,000 Total Device Segment 6,315,000 875,000 22,000 7,212,0000 Clinical Development Segment: Disposables 44,000 -- -- 44,000 Other 5,000 7,000 -- 12,000 Total Clinical Development 49,000 7,000 -- 56,000 Total $ 6,364,000 $ 882,000 $ 22,000 $ 7,268,000 Three Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 849,000 $ 66,000 $ 915,000 BioArchive 449,000 311,000 760,000 Manual Disposables 229,000 -- 229,000 CAR-TXpress 30,000 -- 30,000 Other 8,000 -- $ 16,000 24,000 Total Device Segment 1,565,000 377,000 16,000 1,958,000 Clinical Development Segment: Disposables 1,000 -- -- 1,000 Bone Marrow -- 38,000 -- 38,000 Other -- 7,000 -- 7,000 Total Clinical Development 1,000 45,000 -- 46,000 Total $ 1,566,000 $ 422,000 $ 16,000 $ 2,004,000 Six Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,534,000 $ 131,000 $ 1,665,000 BioArchive 872,000 655,000 1,527,000 Manual Disposables 462,000 -- 462,000 CAR-TXpress 30,000 -- 30,000 Other 46,000 -- $ 33,000 79,000 Total Device Segment 2,944,000 786,000 33,000 3,763,000 Clinical Development Segment: Disposables 23,000 -- -- 23,000 Bone Marrow -- 61,000 -- 61,000 Other -- 24,000 -- 24,000 Total Clinical Development 23,000 85,000 -- 108,000 Total $ 2,967,000 $ 871,000 $ 33,000 $ 3,871,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three six June 30, 2019 $83,000 $446,000, $485,000 $577,000 six June 30, 2019. Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2019 2020 2021 2022 2023 and Beyond Total Service Revenue $ 701,000 $ 786,000 $ 502,000 $ 165,000 $ 120,000 $ 2,274,000 Clinical Revenue 7,000 14,000 14,000 14,000 202,000 251,000 Total $ 708,000 $ 800,000 $ 516,000 $ 179,000 $ 322,000 $ 2,525,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3 Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 540,945 June 30, 2019 June 30: 2019 2018 Common stock equivalents of convertible promissory notes and accrued interest 5,355,198 1,267,607 Vested Series A warrants 40,442 40,442 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,300,091 1,319,728 Stock options 286,229 120,047 Total 7,051,813 2,817,677 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	3 . Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( $8,713,000 $7,200,000 June 30, 2019 December 31, 2018, $1,287,000 may may no The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $16.10 two 2018, $1.80. It was concluded that the conversion option did contain a beneficial conversion feature and as a result of the modifications to the conversion price, the Company recorded a debt discount in the amount of $7,200,000 $1,513,000 March 31, 2019. $586,000 $1,172,000 three six June 30, 2019, $350,000 three six June 30, 2018. $466,000 $926,000 three six June 30, 2019, $382,000 $742,000 three six June 30, 2018. June 30, 2019, $926,000 $1,513,000 December 31, 2018 Distributor Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two Revenues During the three six June 30, 2019, $315,000 $581,000, $43,000 $269,000 three six June 30, 2018 License Agreement On March 12, 2018, X ® Pursuant to the terms of the Agreement, ThermoGenesis has granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X ten may ninety 90 not three six June 30, 2019 2018.

Note 4 - Convertible Promissory

Note 4 - Convertible Promissory Note	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Convertible Promissory Note On January 29, 2019, $800,000 “January 2019 six $1.80 2 90% $0.50 The January 2019 twenty-four 24% January 2019 eighteen 18 January 2019 January 2019 may On the date that is six January 2019 January 2019 January 2019 may January 2019 January 2019 4.99% 9.99% $800,000, May 30, 2019. $57,000 three six June 30, 2019, The January 2019 January 2019 may January 2019

Note 5 - Leases

Note 5 - Leases	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	5. Leases The Company determines if a contract contains a lease at inception. Our material operating lease consists of office space which has a remaining term of 4.9 Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company’s operating leases: June 30, 2019 Right-of-use operating lease assets, net $ 915,000 Current lease liability 102,000 Non-current lease liability 825,000 June 30, 2019 Weighted average remaining lease term 4.9 Discount rate 22 % Maturities of lease liabilities by year for our operating leases are as follows: 2019 (remaining) $ 148,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 2024 138,000 Total lease payments $ 1,545,000 Less: imputed interest (617,000 ) Present value of operating lease liabilities $ 928,000 Statement of Cash Flows In January 2019, $966,000 first 2019. $72,000 $143,000 three six June 30, 2019 Operating Lease Costs Operating lease costs were $103,000 $206,000 three six June 30, 2019. 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively, on the statement of operations. These leases are not June 30, 2019.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6 . Commitments and Contingencies Financial Covenants Effective May 15, 2017, one not $2,000,000. June 30, 2019. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the six June 30, 2019 Balance at December 31, 2018 $ 186,000 Warranties issued during the period 88,000 Settlements made during the period (125,000 ) Changes in liability for pre-existing warranties during the period (17,000 ) Balance at June 30, 2019 $ 132,000 Contingen cies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 $300,000 June 30, 2019) August 2016. October 2017, $1,000,000 June 26, 2018. September 24, 2018, July 22, 2019, August 6, 2019, November 4, 2019. October 30, 2019 No June 30, 2019. In the normal course of operations, the Company may June 30, 2019, may not

Note 7 - Derivative Obligations

Note 7 - Derivative Obligations	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	7 . Derivative Obligations Series A Warrants Series A warrants to purchase 40,442 June 30, 2016. Series A June 30, 2019 December 31, 2018 Market price of common stock $2.81 $2.70 Expected volatility 93% 94% Contractual term (years) 1.7 2.2 Discount rate 1.81% 2.48% Dividend rate 0% 0% Exercise price $80.00 $80.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded no three six June 30, 2019, $308,000 $567,000 three six June 30, 2018, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of June 30, 2019 December 31, 2018: Derivative Obligation June 30, 2019 December 31, 2018 Balance $1,000 $1,000 Level 1 $-- $- Level 2 $-- $- Level 3 $1,000 $1,000 The following table reflects the change in fair value of the Company’s derivative liabilities for the six June 30, 2019: Amount Balance – December 31, 2018 $ 1,000 Change in fair value of derivative obligation -- Balance – June 30, 2019 $ 1,000

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	8 . Stockholders’ Equity Stock Based Compensation The Company recorded stock-based compensation of $125,000 $206,000 three six June 30, 2019, $163,000 $300,000 three six June 30, 2018, Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Cost of revenues $ 1,000 $ 4,000 $ 1,000 $ 7,000 Sales and marketing 44,000 9,000 56,000 17,000 Research and development 22,000 28,000 37,000 55,000 General and administrative 58,000 122,000 112,000 221,000 $ 125,000 $ 163,000 $ 206,000 $ 300,000 The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2018 302,368 $ 13.99 Forfeited (16,139 ) $ 11.71 Outstanding at June 30, 2019 286,229 $ 14.12 9 -- Vested and expected to vest at June 30, 2019 196,219 $ 16.92 8.6 -- Exercisable at June 30, 2019 84,804 $ 28.17 7.7 -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no six June 30, 2019. Warrants A summary of warrant activity for the six June 30, 2019 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2018 1,726,523 $ 29.88 Warrants granted (1) 444,445 $ 0.10 Warrants expired (19,637 ) $ 417.00 Warrants exercised (200,000 ) $ 0.10 Outstanding at June 30, 2019 1,951,331 $ 22.26 Exercisable at June 30, 2019 1,881,478 $ 20.11 ( 1 See Footnote 1

Note 9 - Segment Reporting

Note 9 - Segment Reporting	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	9 . Segment Reporting The Company has two The Clinical Development Segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The following table summarizes the operating results of the Company’s reportable segments: Three Months Ended June 30, 2019 Clinical Development Device Total Net revenues $ 44,000 $ 4,261,000 $ 4,305,000 Cost of revenues 57,000 2,297,000 2,354,000 Gross profit (13,000 ) 1,964,000 1,951,000 Operating expenses 483,000 1,730,000 2,213,000 Operating loss $ (496,000 ) $ 234,000 $ (262,000 ) Depreciation and amortization $ 75,000 $ 115,000 $ 190,000 Stock-based compensation expense $ 59,000 $ 66,000 $ 125,000 Goodwill -- $ 781,000 $ 781,000 Total assets $ 4,412,000 $ 12,120,000 $ 16,532,000 Three Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 46,000 $ 1,958,000 $ 2,004,000 Cost of revenues 49,000 1,592,000 1,641,000 Gross profit (3,000 ) 366,000 363,000 Operating expenses 28,408,000 2,460,000 30,868,000 Operating loss $ (28,411,000 ) $ (2,094,000 ) $ (30,505,000 ) Depreciation and amortization $ 69,000 $ 105,000 $ 174,000 Impairment charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 122,000 $ 41,000 $ 163,000 Goodwill $ 500,000 $ 781,000 $ 1,281,000 Total assets $ 12,808,000 $ 10,435,000 $ 23,243,000 Six Months Ended June 30, 2019 Clinical Development Device Total Net revenues $ 55,000 $ 7,213,000 $ 7,268,000 Cost of revenues 100,000 3,957,000 4,057,000 Gross profit (45,000 ) 3,256,000 3,211,000 Operating expenses 955,000 3,423,000 4,378,000 Operating loss $ (1,000,000 ) $ (167,000 ) $ (1,167,000 ) Depreciation and amortization $ 169,000 $ 233,000 $ 402,000 Stock-based compensation expense $ 113,000 $ 93,000 $ 206,000 Goodwill $ -- $ 781,000 $ 781,000 Total assets $ 4,412,000 $ 12,120,000 $ 16,532,000 Six Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 108,000 $ 3,763,000 $ 3,871,000 Cost of revenues 120,000 3,036,000 3,156,000 Gross profit (12,000 ) 727,000 715,000 Operating expenses 29,588,000 4,889,000 34,477,000 Operating loss $ (29,600,000 ) $ (4,162,000 ) $ (33,762,000 ) Depreciation and amortization $ 137,000 $ 196,000 $ 333,000 Impairment charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 220,000 $ 80,000 $ 300,000 Goodwill $ 500,000 $ 781,000 $ 1,281,000 Total assets $ 12,808,000 $ 10,435,000 $ 23,243,000

Note 10 - Major Customers and A

Note 10 - Major Customers and Accounts Receivable	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	10. Major Customers and Accounts Receivable The Company had certain customers whose revenue individually represented 10% 10% For the three June 30, 2019 2018, one 40% 24% second 18% 0% six June 30, 2019 2018, one 29% 21% another 13% 0% At June 30, 2019, three 79% December 31, 2018 four 77%

Note 11 - Subsequent Events

Note 11 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	11 . S ubsequent Events On July 23, 2019, $1,000,000 “July 2019 six July 2019 $1.80 90% $0.10 August 12, 2019, July 2019 $0.10 $0.50. July 2019 The July 2019 twenty-four 24% July 2019 three July 31, 2022. July 2019 not fourteen July 2019 may On the date that is six July 2019 July 2019 may July 2019 July 2019 4.99% 9.99% In addition, on July 23, 2019, No. 1 January 29, 2019, January 2019 July 29, 2020 July 31, 2022.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 January 1, 2019. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: The following tables summarize the revenues of the Company’s reportable segments: Three Months Ended June 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 3,028,000 $ 54,000 $ 3,082,000 BioArchive 433,000 351,000 784,000 CAR-TXpress 182,000 -- 182,000 Manual Disposables 205,000 -- 205,000 Other -- -- $ 8,000 8,000 Total Device Segment 3,848,000 405,000 8,000 4,261,000 Clinical Development Segment: Disposables 37,000 -- -- 37,000 Other -- 7,000 -- 7,000 Total Clinical Development 37,000 7,000 -- 44,000 Total $ 3,885,000 $ 412,000 $ 8,000 $ 4,305,000 Six Months Ended June 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,295,000 $ 109,000 $ 4,404,000 BioArchive 1,031,000 766,000 1,797,000 Manual Disposables 499,000 -- 499,000 CAR-TXpress 490,000 -- 490,000 Other -- -- $ 22,000 22,000 Total Device Segment 6,315,000 875,000 22,000 7,212,0000 Clinical Development Segment: Disposables 44,000 -- -- 44,000 Other 5,000 7,000 -- 12,000 Total Clinical Development 49,000 7,000 -- 56,000 Total $ 6,364,000 $ 882,000 $ 22,000 $ 7,268,000 Three Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 849,000 $ 66,000 $ 915,000 BioArchive 449,000 311,000 760,000 Manual Disposables 229,000 -- 229,000 CAR-TXpress 30,000 -- 30,000 Other 8,000 -- $ 16,000 24,000 Total Device Segment 1,565,000 377,000 16,000 1,958,000 Clinical Development Segment: Disposables 1,000 -- -- 1,000 Bone Marrow -- 38,000 -- 38,000 Other -- 7,000 -- 7,000 Total Clinical Development 1,000 45,000 -- 46,000 Total $ 1,566,000 $ 422,000 $ 16,000 $ 2,004,000 Six Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,534,000 $ 131,000 $ 1,665,000 BioArchive 872,000 655,000 1,527,000 Manual Disposables 462,000 -- 462,000 CAR-TXpress 30,000 -- 30,000 Other 46,000 -- $ 33,000 79,000 Total Device Segment 2,944,000 786,000 33,000 3,763,000 Clinical Development Segment: Disposables 23,000 -- -- 23,000 Bone Marrow -- 61,000 -- 61,000 Other -- 24,000 -- 24,000 Total Clinical Development 23,000 85,000 -- 108,000 Total $ 2,967,000 $ 871,000 $ 33,000 $ 3,871,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three June 30, 2019 $406,000. $485,000 $577,000 six June 30, 2019. Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2019 2020 2021 2022 2023 and Beyond Total Service Revenue $ 701,000 $ 786,000 $ 502,000 $ 165,000 $ 120,000 $ 2,274,000 Clinical Revenue 7,000 14,000 14,000 14,000 202,000 251,000 Total $ 708,000 $ 800,000 $ 516,000 $ 179,000 $ 322,000 $ 2,525,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 540,945 June 30, 2019 June 30: 2019 2018 Common stock equivalents of convertible promissory notes and accrued interest 5,355,198 1,267,607 Vested Series A warrants 40,442 40,442 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,300,091 1,319,728 Stock options 286,229 120,047 Total 7,051,813 2,817,677 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 3,028,000 $ 54,000 $ 3,082,000 BioArchive 433,000 351,000 784,000 CAR-TXpress 182,000 -- 182,000 Manual Disposables 205,000 -- 205,000 Other -- -- $ 8,000 8,000 Total Device Segment 3,848,000 405,000 8,000 4,261,000 Clinical Development Segment: Disposables 37,000 -- -- 37,000 Other -- 7,000 -- 7,000 Total Clinical Development 37,000 7,000 -- 44,000 Total $ 3,885,000 $ 412,000 $ 8,000 $ 4,305,000 Six Months Ended June 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,295,000 $ 109,000 $ 4,404,000 BioArchive 1,031,000 766,000 1,797,000 Manual Disposables 499,000 -- 499,000 CAR-TXpress 490,000 -- 490,000 Other -- -- $ 22,000 22,000 Total Device Segment 6,315,000 875,000 22,000 7,212,0000 Clinical Development Segment: Disposables 44,000 -- -- 44,000 Other 5,000 7,000 -- 12,000 Total Clinical Development 49,000 7,000 -- 56,000 Total $ 6,364,000 $ 882,000 $ 22,000 $ 7,268,000 Three Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 849,000 $ 66,000 $ 915,000 BioArchive 449,000 311,000 760,000 Manual Disposables 229,000 -- 229,000 CAR-TXpress 30,000 -- 30,000 Other 8,000 -- $ 16,000 24,000 Total Device Segment 1,565,000 377,000 16,000 1,958,000 Clinical Development Segment: Disposables 1,000 -- -- 1,000 Bone Marrow -- 38,000 -- 38,000 Other -- 7,000 -- 7,000 Total Clinical Development 1,000 45,000 -- 46,000 Total $ 1,566,000 $ 422,000 $ 16,000 $ 2,004,000 Six Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,534,000 $ 131,000 $ 1,665,000 BioArchive 872,000 655,000 1,527,000 Manual Disposables 462,000 -- 462,000 CAR-TXpress 30,000 -- 30,000 Other 46,000 -- $ 33,000 79,000 Total Device Segment 2,944,000 786,000 33,000 3,763,000 Clinical Development Segment: Disposables 23,000 -- -- 23,000 Bone Marrow -- 61,000 -- 61,000 Other -- 24,000 -- 24,000 Total Clinical Development 23,000 85,000 -- 108,000 Total $ 2,967,000 $ 871,000 $ 33,000 $ 3,871,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2019 2020 2021 2022 2023 and Beyond Total Service Revenue $ 701,000 $ 786,000 $ 502,000 $ 165,000 $ 120,000 $ 2,274,000 Clinical Revenue 7,000 14,000 14,000 14,000 202,000 251,000 Total $ 708,000 $ 800,000 $ 516,000 $ 179,000 $ 322,000 $ 2,525,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2019 2018 Common stock equivalents of convertible promissory notes and accrued interest 5,355,198 1,267,607 Vested Series A warrants 40,442 40,442 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,300,091 1,319,728 Stock options 286,229 120,047 Total 7,051,813 2,817,677

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	June 30, 2019 Right-of-use operating lease assets, net $ 915,000 Current lease liability 102,000 Non-current lease liability 825,000 June 30, 2019 Weighted average remaining lease term 4.9 Discount rate 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2019 (remaining) $ 148,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 2024 138,000 Total lease payments $ 1,545,000 Less: imputed interest (617,000 ) Present value of operating lease liabilities $ 928,000

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2018 $ 186,000 Warranties issued during the period 88,000 Settlements made during the period (125,000 ) Changes in liability for pre-existing warranties during the period (17,000 ) Balance at June 30, 2019 $ 132,000

Note 7 - Derivative Obligatio_2

Note 7 - Derivative Obligations (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series A June 30, 2019 December 31, 2018 Market price of common stock $2.81 $2.70 Expected volatility 93% 94% Contractual term (years) 1.7 2.2 Discount rate 1.81% 2.48% Dividend rate 0% 0% Exercise price $80.00 $80.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Derivative Obligation June 30, 2019 December 31, 2018 Balance $1,000 $1,000 Level 1 $-- $- Level 2 $-- $- Level 3 $1,000 $1,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – December 31, 2018 $ 1,000 Change in fair value of derivative obligation -- Balance – June 30, 2019 $ 1,000

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Cost of revenues $ 1,000 $ 4,000 $ 1,000 $ 7,000 Sales and marketing 44,000 9,000 56,000 17,000 Research and development 22,000 28,000 37,000 55,000 General and administrative 58,000 122,000 112,000 221,000 $ 125,000 $ 163,000 $ 206,000 $ 300,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2018 302,368 $ 13.99 Forfeited (16,139 ) $ 11.71 Outstanding at June 30, 2019 286,229 $ 14.12 9 -- Vested and expected to vest at June 30, 2019 196,219 $ 16.92 8.6 -- Exercisable at June 30, 2019 84,804 $ 28.17 7.7 --
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2018 1,726,523 $ 29.88 Warrants granted (1) 444,445 $ 0.10 Warrants expired (19,637 ) $ 417.00 Warrants exercised (200,000 ) $ 0.10 Outstanding at June 30, 2019 1,951,331 $ 22.26 Exercisable at June 30, 2019 1,881,478 $ 20.11

Note 9 - Segment Reporting (Tab

Note 9 - Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Three Months Ended June 30, 2019 Clinical Development Device Total Net revenues $ 44,000 $ 4,261,000 $ 4,305,000 Cost of revenues 57,000 2,297,000 2,354,000 Gross profit (13,000 ) 1,964,000 1,951,000 Operating expenses 483,000 1,730,000 2,213,000 Operating loss $ (496,000 ) $ 234,000 $ (262,000 ) Depreciation and amortization $ 75,000 $ 115,000 $ 190,000 Stock-based compensation expense $ 59,000 $ 66,000 $ 125,000 Goodwill -- $ 781,000 $ 781,000 Total assets $ 4,412,000 $ 12,120,000 $ 16,532,000 Three Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 46,000 $ 1,958,000 $ 2,004,000 Cost of revenues 49,000 1,592,000 1,641,000 Gross profit (3,000 ) 366,000 363,000 Operating expenses 28,408,000 2,460,000 30,868,000 Operating loss $ (28,411,000 ) $ (2,094,000 ) $ (30,505,000 ) Depreciation and amortization $ 69,000 $ 105,000 $ 174,000 Impairment charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 122,000 $ 41,000 $ 163,000 Goodwill $ 500,000 $ 781,000 $ 1,281,000 Total assets $ 12,808,000 $ 10,435,000 $ 23,243,000 Six Months Ended June 30, 2019 Clinical Development Device Total Net revenues $ 55,000 $ 7,213,000 $ 7,268,000 Cost of revenues 100,000 3,957,000 4,057,000 Gross profit (45,000 ) 3,256,000 3,211,000 Operating expenses 955,000 3,423,000 4,378,000 Operating loss $ (1,000,000 ) $ (167,000 ) $ (1,167,000 ) Depreciation and amortization $ 169,000 $ 233,000 $ 402,000 Stock-based compensation expense $ 113,000 $ 93,000 $ 206,000 Goodwill $ -- $ 781,000 $ 781,000 Total assets $ 4,412,000 $ 12,120,000 $ 16,532,000 Six Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 108,000 $ 3,763,000 $ 3,871,000 Cost of revenues 120,000 3,036,000 3,156,000 Gross profit (12,000 ) 727,000 715,000 Operating expenses 29,588,000 4,889,000 34,477,000 Operating loss $ (29,600,000 ) $ (4,162,000 ) $ (33,762,000 ) Depreciation and amortization $ 137,000 $ 196,000 $ 333,000 Impairment charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 220,000 $ 80,000 $ 300,000 Goodwill $ 500,000 $ 781,000 $ 1,281,000 Total assets $ 12,808,000 $ 10,435,000 $ 23,243,000

Note 1 - Description of Busin_2

Note 1 - Description of Business and Basis of Presentation (Details Textual)		Jun. 04, 2019	Apr. 18, 2019USD ($)$ / sharesshares	Jun. 30, 2019USD ($)shares	Mar. 31, 2019USD ($)	Jun. 30, 2019USD ($)shares	Jan. 01, 2019	Dec. 31, 2018USD ($)shares	Mar. 31, 2017USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance				$ 778,000		$ 778,000		$ (1,711,000)
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Common Stock, Shares Authorized | shares				350,000,000		350,000,000		350,000,000
Class of Warrant or Right, Issued During Period | shares	[1]					444,445
Cash and Cash Equivalents, at Carrying Value, Ending Balance				$ 2,424,000		$ 2,424,000		$ 2,400,000
Working Capital				3,374,000		3,374,000
Retained Earnings (Accumulated Deficit), Ending Balance				(230,603,000)		(230,603,000)		$ (227,435,000)
April 2019 Pre-funded Warrants [Member]
Class of Warrant or Right, Issued During Period | shares			444,445
Warrants Issued, Price Per Warrant | $ / shares			$ 1.70
Proceeds from Issuance of Warrants			$ 756,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.10
April 2019 Pre-funded Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Maximum Percentage of Outstanding Stock Ownership Limitation			4.99%
April 2019 Pre-funded Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Maximum Percentage of Outstanding Stock Ownership Limitation			9.99%
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total				8,713,000		8,713,000
Line of Credit Facility, Maximum Borrowing Capacity				10,000,000		10,000,000			$ 10,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		10
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest				2,843,000	$ 2,843,000
ThermoGenesis [Member]
Ownership in Subsidiary Exchanged							20.00%
Noncontrolling Interest, Ownership Percentage by Parent							100.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance				(1,711,000)		(1,711,000)
CAR-TXpress [Member]
Minority Interest Acquired Through Exchange							20.00%
Noncontrolling Interest, Ownership Percentage by Parent							80.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance				$ 1,100,000		$ 1,100,000
[1]	See Footnote 1 of the Notes to the Condensed Consolidated Financial Statements.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)shares	Jun. 30, 2018shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Right-of-Use Asset	$ 915,000	$ 915,000
Contract with Customer, Liability, Revenue Recognized	83,000	446,000
Contract with Customer, Liability, Current	577,000	$ 577,000			$ 485,000
Number of Reportable Segments		2
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		7,051,813	2,817,677
Operating Lease, Liability, Total	$ 928,000	$ 928,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		540,945
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 966,000
Operating Lease, Liability, Total				$ 966,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net revenues	$ 4,305,000	$ 2,004,000	$ 7,268,000	$ 3,871,000
Device [Member]
Net revenues	4,261,000	1,958,000	72,120,000	3,763,000
Device [Member] | AXP [Member]
Net revenues	3,082,000	915,000	4,404,000	1,665,000
Device [Member] | BioArchive [Member]
Net revenues	784,000	760,000	1,797,000	1,527,000
Device [Member] | CAR-TXpress [Member]
Net revenues	182,000	30,000	490,000	30,000
Device [Member] | Manual Disposables [Member]
Net revenues	205,000	229,000	499,000	462,000
Device [Member] | Other Subsegments [Member]
Net revenues	8,000	24,000	22,000	79,000
Clinical Development [Member]
Net revenues	44,000	46,000	56,000	108,000
Clinical Development [Member] | Manual Disposables [Member]
Net revenues	37,000	1,000	44,000	23,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues	7,000	7,000	12,000	24,000
Clinical Development [Member] | Bone Marrow [Member]
Net revenues		38,000		61,000
Device Revenue [Member]
Net revenues	3,885,000	1,566,000	6,364,000	2,967,000
Device Revenue [Member] | Device [Member]
Net revenues	3,848,000	1,565,000	6,315,000	2,944,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	3,028,000	849,000	4,295,000	1,534,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	433,000	449,000	1,031,000	872,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	182,000	30,000	490,000	30,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	205,000	229,000	499,000	462,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues		8,000		46,000
Device Revenue [Member] | Clinical Development [Member]
Net revenues	37,000	1,000	49,000	23,000
Device Revenue [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues	37,000	1,000	44,000	23,000
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues			5,000
Device Revenue [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues
Service [Member]
Net revenues	412,000	422,000	882,000	871,000
Service [Member] | Device [Member]
Net revenues	405,000	377,000	875,000	786,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	54,000	66,000	109,000	131,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	351,000	311,000	766,000	655,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Clinical Development [Member]
Net revenues	7,000	45,000	7,000	85,000
Service [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues	7,000	7,000	7,000	24,000
Service [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues		38,000		61,000
Other [Member]
Net revenues	8,000	16,000	22,000	33,000
Other [Member] | Device [Member]
Net revenues	8,000	16,000	22,000	33,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	8,000	16,000	22,000	33,000
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Jun. 30, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 2,525,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,274,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 251,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Jun. 30, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 2,525,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Revenue, Remaining Performance Obligation, Amount	$ 708,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	182 days
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Amount	$ 800,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Amount	$ 516,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Amount	$ 179,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 322,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,274,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Revenue, Remaining Performance Obligation, Amount	$ 701,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	182 days
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Amount	$ 786,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Amount	$ 502,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Amount	$ 165,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 120,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 251,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Revenue, Remaining Performance Obligation, Amount	$ 7,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	182 days
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 202,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018
Anti-dilutive securities (in shares)		7,051,813	2,817,677
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		5,355,198	1,267,607
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		40,442	40,442
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	69,853	69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		1,300,091	1,319,728
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		286,229	120,047
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($)	Mar. 12, 2018	Aug. 21, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Apr. 16, 2018	Apr. 01, 2018	Mar. 31, 2017
Amortization of Debt Discount (Premium)					$ 1,229,000	$ 350,000
Interest Expense, Total			$ 1,211,000	$ 733,000	2,343,000	1,093,000
Adjustments for New Accounting Principle, Early Adoption [Member] | Accounting Standards Update 2017-11 [Member]
Debt Instrument, Unamortized Discount, Total			1,513,000		1,513,000				$ 7,200,000
Amortization of Debt Discount (Premium)			586,000	350,000	1,172,000	350,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price							$ 1.80	$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			10,000,000		10,000,000					$ 10,000,000
Proceeds from Long-term Lines of Credit					8,713,000		$ 7,200,000
Line of Credit Facility, Remaining Borrowing Capacity			$ 1,287,000		$ 1,287,000
Debt Instrument, Interest Rate, Stated Percentage			22.00%		22.00%
Interest Expense, Total			$ 466,000	382,000	$ 926,000	742,000
Interest Payable			926,000		926,000		$ 1,513,000
Boyalife W.S.N. [Member]
Distributor Agreement Term		3 years
Distributor Agreement, Renewal Term		2 years
Revenue from Related Parties			$ 315,000	$ 43,000	$ 581,000	$ 269,000
IncoCell [Member]
Contract Development Revenue, Term	10 years

Note 4 - Convertible Promisso_2

Note 4 - Convertible Promissory Note (Details Textual) - USD ($)	Jan. 29, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	May 30, 2019
Amortization of Debt Discount (Premium)			$ 1,229,000	$ 350,000
Convertible Debt [Member] | Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%
Debt Instrument, Term	1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers	4.99%
Debt Instrument, Convertible, Second customary conversion blockers	9.99%
Debt Instrument, Unamortized Discount, Total					$ 800,000
Amortization of Debt Discount (Premium)		$ 57,000	$ 57,000
Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount	$ 800,000
Debt Instrument, Convertible, Conversion Price	$ 1.80
Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.50

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Operating Lease, Weighted Average Remaining Lease Term	4 years 328 days		4 years 328 days
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability		$ 966,000	$ 966,000
Operating Lease, Payments	$ 72,000		143,000
Operating Lease, Cost	$ 103,000		$ 206,000

Note 5 - Leases - Lease Informa

Note 5 - Leases - Lease Information (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Right-of-use operating lease assets, net	$ 915,000
Current lease liability	102,000
Non-current lease liability	$ 825,000
Weighted average remaining lease term (Year)	4 years 328 days
Discount rate	22.00%

Note 5 - Leases - Maturities of

Note 5 - Leases - Maturities of Lease Liabilities (Details)	Jun. 30, 2019USD ($)
2019 (remaining)	$ 148,000
2020	301,000
2021	310,000
2022	319,000
2023	329,000
2024	138,000
Total lease payments	1,545,000
Less: imputed interest	(617,000)
Present value of operating lease liabilities	$ 928,000

Note 6 - Commitments and Cont_3

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	May 04, 2017	Oct. 31, 2017	Jun. 30, 2019
Payment Terms, Severance Compensation			1 year
Short Term Investment Minimum			$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Loss Contingency, Damages Sought, Value, Interest			300,000
Loss Contingency, Negotiation Condition Bond		$ 1,000,000
Loss Contingency Accrual, Ending Balance			$ 0

Note 6 - Commitments and Cont_4

Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	6 Months Ended
	Jun. 30, 2019USD ($)
Balance	$ 186,000
Warranties issued during the period	88,000
Settlements made during the period	(125,000)
Changes in liability for pre-existing warranties during the period	(17,000)
Balance	$ 132,000

Note 7 - Derivative Obligatio_3

Note 7 - Derivative Obligations (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Jun. 30, 2016
Class of Warrant or Right, Outstanding	1,951,331		1,951,331		1,726,523
Derivative, Gain (Loss) on Derivative, Net, Total	$ 0	$ 308,000	$ 0	$ 567,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding						40,442

Note 7 - Derivative Obligatio_4

Note 7 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Jun. 30, 2019	Dec. 31, 2018
Measurement Input, Share Price [Member]
Valuation assumption	2.81	2.7
Measurement Input, Price Volatility [Member]
Valuation assumption	0.93	0.94
Measurement Input, Expected Term [Member]
Valuation assumption	1.7	2.2
Measurement Input, Discount Rate [Member]
Valuation assumption	0.0181	0.0248
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	80	80

Note 7 - Derivative Obligatio_5

Note 7 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Derivative obligations	$ 1,000	$ 1,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 1,000	$ 1,000

Note 7 - Derivative Obligatio_6

Note 7 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Balance			$ 1,000
Change in fair value of derivative obligation	$ 0	$ (308,000)	0	$ (567,000)
Balance	$ 1,000		$ 1,000

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Expense	$ 125,000	$ 163,000	$ 206,000	$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			0

Note 8 - Stockholder's Equity -

Note 8 - Stockholder's Equity - Stock-based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Expense	$ 125,000	$ 163,000	$ 206,000	$ 300,000
Cost of Sales [Member]
Share-based Payment Arrangement, Expense	1,000	4,000	1,000	7,000
Selling and Marketing Expense [Member]
Share-based Payment Arrangement, Expense	44,000	9,000	56,000	17,000
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	22,000	28,000	37,000	55,000
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense	$ 58,000	$ 122,000	$ 112,000	$ 221,000

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	6 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	302,368
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 13.99
Forfeited, options (in shares) | shares	(16,139)
Forfeited, weighted average exercise price, options (in dollars per share) | $ / shares	$ 11.71
Outstanding, options (in shares) | shares	286,229
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 14.12
Outstanding, weighted average remaining contractual life, options (Year)	9 years
Outstanding, aggregate intrinsic value, options | $
Vested and Expected to Vest, options (in shares) | shares	196,219
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 16.92
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	8 years 219 days
Vested and Expected to Vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	84,804
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 28.17
Exercisable, weighted average remaining contractual life, options (Year)	7 years 255 days
Exercisable, aggregate intrinsic value, options | $

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity - Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Outstanding (in shares) | shares	1,726,523
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 29.88
Warrants granted(1) (in shares) | shares	444,445	[1]
Warrants granted(1) (in dollars per share) | $ / shares	$ 0.10	[1]
Warrants expired (in shares) | shares	(19,637)
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares	$ 417
Warrants exercised (in shares) | shares	(200,000)
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.10
Outstanding (in shares) | shares	1,951,331
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 22.26
Exercisable (in shares) | shares	1,881,478
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 20.11
[1]	See Footnote 1 of the Notes to the Condensed Consolidated Financial Statements.

Note 9 - Segment Reporting (Det

Note 9 - Segment Reporting (Details Textual)	6 Months Ended
	Jun. 30, 2019
Number of Reportable Segments	2

Note 9 - Segment Reporting - Su

Note 9 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Net revenues	$ 4,305,000	$ 2,004,000	$ 7,268,000	$ 3,871,000
Cost of revenues	2,354,000	1,641,000	4,057,000	3,156,000
Gross profit	1,951,000	363,000	3,211,000	715,000
Operating expenses	2,213,000	30,868,000	4,378,000	34,477,000
Operating loss	(262,000)	(30,505,000)	(1,167,000)	(33,762,000)
Depreciation and amortization	190,000	174,000	402,000	333,000
Stock-based compensation expense	125,000	163,000	206,000	300,000
Goodwill	781,000	1,281,000	781,000	1,281,000	$ 781,000
Total assets	16,532,000	23,243,000	16,532,000	23,243,000	$ 14,611,000
Impairment charges		27,202,000		27,202,000
Clinical Development [Member]
Net revenues	44,000	46,000	56,000	108,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	44,000	46,000	55,000	108,000
Cost of revenues	57,000	49,000	100,000	120,000
Gross profit	(13,000)	(3,000)	(45,000)	(12,000)
Operating expenses	483,000	28,408,000	955,000	29,588,000
Operating loss	(496,000)	(28,411,000)	(1,000,000)	(29,600,000)
Depreciation and amortization	75,000	69,000	169,000	137,000
Stock-based compensation expense	59,000	122,000	113,000	220,000
Goodwill		500,000		500,000
Total assets	4,412,000	12,808,000	4,412,000	12,808,000
Impairment charges		27,202,000		27,202,000
Device [Member]
Net revenues	4,261,000	1,958,000	72,120,000	3,763,000
Device [Member] | Operating Segments [Member]
Net revenues	4,261,000	1,958,000	7,213,000	3,763,000
Cost of revenues	2,297,000	1,592,000	3,957,000	3,036,000
Gross profit	1,964,000	366,000	3,256,000	727,000
Operating expenses	1,730,000	2,460,000	3,423,000	4,889,000
Operating loss	234,000	(2,094,000)	(167,000)	(4,162,000)
Depreciation and amortization	115,000	105,000	233,000	196,000
Stock-based compensation expense	66,000	41,000	93,000	80,000
Goodwill	781,000	781,000	781,000	781,000
Total assets	$ 12,120,000	10,435,000	$ 12,120,000	10,435,000
Impairment charges

Note 10 - Major Customers and_2

Note 10 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member]	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue Benchmark [Member] | Customer 1 [Member]
Concentration Risk, Percentage			40.00%	24.00%	29.00%	21.00%
Revenue Benchmark [Member] | Customer 2 [Member]
Concentration Risk, Percentage			18.00%	0.00%	13.00%	0.00%
Accounts Receivable [Member]
Number of Major Customers	3	4
Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage	79.00%
Accounts Receivable [Member] | Four Customers [Member]
Concentration Risk, Percentage		77.00%

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Convertible Debt [Member] - The July 2019 Note [Member] - USD ($)	Jul. 23, 2019	Aug. 12, 2019
Debt Instrument, Face Amount	$ 1,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%
Debt Instrument, Term	3 years
Debt Instrument, Convertible, First Customary Conversion Blockers	4.99%
Debt Instrument, Convertible, Second customary conversion blockers	9.99%
Maximum [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.80
Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.10	$ 0.50